Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Subscribe To Our Newsletter & Stay Updated